Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IH-2014A regimen
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Intramuscular, Intrathecal
01
Overview
IH-2014A is a multi-agent chemotherapy regimen developed by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS) for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). The regimen is a risk-stratified protocol that includes an induction phase, consolidation, and maintenance therapy. The induction phase typically utilizes the VDCLP backbone, consisting of vincristine, daunorubicin, cyclophosphamide, L-asparaginase (or PEG-asparaginase), and prednisone. Consolidation therapy involves high-dose methotrexate, cytarabine, etoposide, and 6-mercaptopurine. The IH-2014A regimen aims to optimize complete remission rates and overall survival while managing treatment-related toxicities in the Chinese adult ALL population.
- Other names
- IH-2014 protocolIH2014 protocolIH 2014 protocol
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DHFR (Dihydrofolate reductase)HPRT1 (Hypoxanthine-guanine phosphoribosyltransferase)DNA polymerase familyGR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on IH-2014A regimen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IH-2014A regimen.